ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?

Autor: Hansford JR; Michael Rice Centre for Hematology and Oncology, Women's and Children's Hospital, Adelaide, SA, Australia.; Paediatric Neuro-Oncology, Cancer Precision Medicine, South Australia Health and Medical Research Institute, Adelaide, SA, Australia.; South Australia ImmunoGENomics Cancer Institute, University of Adelaide, Adelaide, SA, Australia., Manoharan N; Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.; Children's Cancer Institute, Lowy Cancer Centre, UNSW Sydney, Kensington, NSW, Australia.; School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Kensington, NSW, Australia., Bouche G; The Anticancer Fund, Meise, Belgium., Ramaswamy V; Developmental and Stem Cell Biology, Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Canada.; Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.; Departments of Medical Biophysicsand Pediatrics, University of Toronto, Toronto, ON, Canada., Jabado N; Department of Pediatrics, McGill University, RI-MUHC, Glen Site, Montreal, QC, Canada., Bouffet E; The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Jazyk: angličtina
Zdroj: Expert opinion on emerging drugs [Expert Opin Emerg Drugs] 2024 Dec; Vol. 29 (4), pp. 321-325. Date of Electronic Publication: 2024 Nov 21.
DOI: 10.1080/14728214.2024.2426649
Databáze: MEDLINE